Kolibri
Making the gene therapy promise a reality using acoustic-based bioproduction technologies
Gene therapies are game changers to treat incurable genetic diseases and cancers.
With production costs superior to 1m$/patient, large scale manufacturing of their key component, viral vectors, remains the blocking point to scale up and make gene therapies more affordable.
Kolibri creates the next-generation of bioproduction technologies reducing viral vector production costs up to 95%. Their proprietary bioreactor combines cutting edge acoustic techniques to drastically reduce the cost of manufacturing and further increase the quality of the end-product.
Founders
Amélie Quilichini
CEO, Kolibri
Engineer with experience in managing tech & hardware projects as a strategy consultant
Gabriel Dumy
CTO, Kolibri
PhD in acoustophoresis with experience in developing cell growing acoustic devices